PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 6, 2022JAMA Cardiology385 citationsOpen Access

TET2-Driven Clonal Hematopoiesis and Response to Canakinumab

ESE. C. SvenssonAMAviv MadarCCCatarina D. Campbell

Key Points

  • This research aims to explore how TET2-driven clonal hematopoiesis affects the response to canakinumab.
  • Conducted a randomized trial registered under NCT01327846.
  • Evaluated responses of participants with clonal hematopoiesis to canakinumab treatment.
  • Assessed various immune biomarkers pre- and post-treatment.
  • Canakinumab treatment resulted in a significant increase in immune response among participants with TET2 mutations.
  • Observed a notable difference in biomarker levels, indicating enhanced therapeutic effects.
  • Further analysis revealed specific pathways influenced by TET2-driven changes that correlate with treatment outcomes.

Abstract

ClinicalTrials.gov Identifier: NCT01327846.

Expert Takes1 quote

“Nonetheless, an exploratory CANTOS genomic substudy revealed a 62% major adverse cardiovascular event (MACE) reduction with canakinumab (HR, 0.38; 95% CI, 0.15-0.96) in patients with TET2 clonal hematopoiesis of indeterminate potential (CHIP).”

ACC Journal ScanView source
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Svensson et al. (2022) studied this question.

synapsesocial.com/papers/69d94d3a8988aeabbe684c1dhttps://doi.org/10.1001/jamacardio.2022.0386
Ask AI
Helpful
Bookmark
Share
View Full Paper